Fierce Pharma3h
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
BioSpace3d
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
Medscape2d
Drug Labels Often Neglect to Inform About Obesity Dosing
Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...
pharmaphorum5h
Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...
The Washington Post13d
FDA says Ozempic shortage is over, chilling boom in off-brand versions
As drugmakers Novo Nordisk and Eli Lilly struggled to keep up with enormous demand for their diabetes and obesity drugs, the ...
BioSpace1d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Global obesity crisis: 60% of adults and one-third of children could be overweight by 2050
A study published on Tuesday in 'The Lancet' warns of the escalation of the obesity and overweight pandemic if no action is ...
Trump FDA Pick Makary Endorses RFK Jr.’s Transparency Pledge
Marty Makary, President Donald Trump’s pick to lead the US Food and Drug Administration, said he’s ready to carry out the ...
USA TODAY on MSN12d
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in ...